Workflow
Globenewswire
icon
Search documents
Regency Centers to Present at Citi’s 2026 Global Property CEO Conference
Globenewswire· 2026-02-24 21:15
JACKSONVILLE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency” or the “Company”) (Nasdaq: REG) today announced that the Company’s management team is scheduled to present at the 2026 Citi Global Property CEO Conference (the “Conference”) on Monday, March 2, 2026, at 8:50 am ET. To access the Company’s live presentation, use the webcast registration link below. Regency Centers PresentationDate:Monday, March 2, 2026Time:8:50 a.m. – 9:25 a.m. ETWebcast Link:Citi's 2026 Global Prope ...
Tandy Leather Factory Reports Fourth Quarter and Full Year 2025 Results
Globenewswire· 2026-02-24 21:15
BENBROOK, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the fourth fiscal quarter and full year 2025. Highlights from 2025: Revenues were $76.3 million, up 2.6% from 2024Generated operating loss of $1.0 million versus income of $0.6 million in 2024Net income of $9.1 million versus $0.8 million in 2024Gross margins of 57.0%, up from 56.2% in 2024Operating expenses $44.5 million, up 8.1% from 2024Adjusted EBITDA* (from op ...
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Globenewswire· 2026-02-24 21:10
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 202 ...
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
Globenewswire· 2026-02-24 21:09
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Comp ...
Pomerantz Law Firm Announces the Filing of a Class Action Against Lakeland Industries, Inc.and Certain Officers – LAKE
Globenewswire· 2026-02-24 21:08
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lakeland Industries, Inc. (“Lakeland” or the “Company”) (NASDAQ: LAKE) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-01501, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lakeland securities between December 1, 2023 ...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Endeavor Group Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EDR
Globenewswire· 2026-02-24 21:08
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of Endeavor Group Holdings, Inc. (NYSE: EDR) Class A common stock between January 15, 2025 and March 24, 2025, both dates inclusive (the “Class Period”), of the important March 18, 2026 lead plaintiff deadline. SO WHAT: If you sold Endeavor Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT
Globenewswire· 2026-02-24 21:08
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026. SO WHAT: If you purchased Corcept common stock during the Class P ...
Valley National Bancorp Announces Adoption of Share Repurchase Program
Globenewswire· 2026-02-24 21:06
Stock Repurchase Program - Valley National Bancorp's Board of Directors approved a new stock repurchase program for up to 25 million shares of common stock, effective from April 27, 2026, to April 27, 2028 [1][2] - The current stock repurchase program is set to expire on April 26, 2026, unless terminated sooner [1] Repurchase Methods and Flexibility - Repurchases can be conducted through various methods, including open market purchases and Rule 10b5-1 trading plans, in compliance with SEC regulations [2] - The program does not obligate Valley to acquire a specific number of shares and can be suspended or discontinued at the company's discretion [2] Company Overview - Valley National Bank, a regional financial institution and principal subsidiary of Valley National Bancorp, has approximately $64 billion in assets and operates over 200 offices across several states [3] - The bank offers a full range of consumer, commercial, and wealth management solutions, emphasizing a relationship-led approach to support community investment and corporate citizenship [3]
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globenewswire· 2026-02-24 21:05
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose Exp ...
Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance
Globenewswire· 2026-02-24 21:05
Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* an ...